SLC16A1 and prostate adenocarcinoma: While this agrees with some prior studies investigating prostate MCT1 expression using IHC40,41, the TCGA-PRAD derived mRNA data42 showed a significant overexpression of SLC16A1 (MCT1) in tumour samples compared to benign surgical specimens (P = 0.009; Fig. 2m).